162 related articles for article (PubMed ID: 31764168)
1. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies.
Sterner RM; Kenderian SS
Curr Opin Hematol; 2020 Jan; 27(1):41-48. PubMed ID: 31764168
[TBL] [Abstract][Full Text] [Related]
2. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
4. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
6. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
7. Current challenges for CAR T-cell therapy of acute myeloid leukemia.
Sauer T; Rooney CM
Transfusion; 2019 Apr; 59(4):1171-1173. PubMed ID: 30762880
[TBL] [Abstract][Full Text] [Related]
8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
10. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
11. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
12. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome: grading, modeling, and new therapy.
Liu D; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
16. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
17. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
18. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
19. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.
Wang Y; Jiang H; Luo H; Sun Y; Shi B; Sun R; Li Z
Front Immunol; 2019; 10():1691. PubMed ID: 31379876
[TBL] [Abstract][Full Text] [Related]
20. Special delivery! CAR-T cells transport RN7SL1 to the tumor microenvironment.
Nutt WS; Srivastava S
Trends Mol Med; 2021 Nov; 27(11):1019-1021. PubMed ID: 34593322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]